APYX Medical Corp (NASDAQ:APYX) Reports Mixed Q2 2025 Earnings with Revenue Miss and Narrower Loss

APYX MEDICAL CORP (NASDAQ:APYX) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. The company, known for its helium plasma and radiofrequency technology used in cosmetic and surgical markets, posted revenue of $11.37 million, falling short of the consensus estimate of $11.93 million. Earnings per share (EPS) came in at -$0.09, slightly better than the anticipated -$0.095.

Key Financial Highlights

• Revenue Miss: Reported revenue of $11.37 million was 4.7% below analyst expectations.
• Narrower Loss: The EPS loss of $0.09 was marginally better than the estimated -$0.095.
• Full-Year Estimates: Analysts project full-year 2025 revenue at $49.18 million, with an EPS loss of -$0.367.
• Q3 Outlook: For the next quarter, revenue is forecasted at $11.97 million, with an expected EPS loss of -$0.099.

Market Reaction

The stock has shown muted movement in after-hours trading, with no significant price change following the earnings release. Over the past month, shares have declined by 10.5%, reflecting broader investor caution. However, the stock has seen a 7.4% uptick in the last week, suggesting some optimism ahead of the earnings announcement.

Operational Developments

The company highlighted progress in its commercial strategy, including the successful launch of its AYON Body Contouring System™ to key surgeons ahead of a planned broader rollout in September 2025. This product expansion could play a role in future revenue growth, though the immediate financial impact was not substantial enough to meet Q2 expectations.

Additionally, Apyx Medical disclosed an inducement grant under Nasdaq rules, awarding 100,000 stock options to its Vice President of North American Sales, John Featherstone. While this is a routine corporate action, it underscores efforts to retain key personnel amid ongoing commercialization efforts.

Looking Ahead

The company did not provide explicit forward guidance in its press release, leaving investors to rely on analyst projections. The slight earnings beat may offer some reassurance, but the revenue miss and continued losses suggest challenges in scaling operations. The upcoming commercial launch of the AYON system will be a critical milestone to watch.

For a deeper dive into Apyx Medical’s earnings and analyst estimates, visit the earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.